Good morning, everyone, and how are you today? Another sunny summer day is unfolding over the Pharmalot corporate campus, where we are enjoying the chirping birds and a cool breeze wafting through the windows. This calls for a celebratory cup of stimulation, which is much needed, actually, since there is a great deal to do today. We assume you can relate. After all, the summer doldrums may be upon us, but the world keeps spinning. So time to get started. Here are a few tidbits. Dig in and have a great day. Catch you soon...
Top FDA Officials Knew Of E-mail Monitoring (Wall Street Journal)
Chemotherapy Can Backfire And Cause Cancer Growth (Agence France-Presse)
J&J Faces Inquiries Into Marketing Of Two Other Drugs (Dow Jones)
Pluristem Stem Cell Therapy Saves Second Patient (Globes)
China Detains 2,000 People In Counterfeit Drug Sweep (Reuters)
Mylan Launches 18 HIV Drugs In India (Pharma Times)
Research On Pain Meds Seeks A Genetic Link (Wall Street Journal)
J&J Looks To Trim Ad Agencies (Advertising Age)
Pfizer Dodges Claim For Another Bextra Payout (Courthouse News)
EDITOR'S NOTE: Please check this post for updates during the day
steaming coffee pic thx to dleggett on flickr
1 Comment
By examining drug-induced cell death events in native-state 3D (three-dimensional) microclusters, the functional profiling platform has the unique capacity to capture stromal, cytokines, macrophages, lymphocytes, mesenchymal cells, fibroblasts, smooth muscle cells, pericytes, vascular and inflammatory cell interactions with tumor cells, known to be crucial for clinical response prediction.
The microclusters recapitulate the human tumor environment, while the "3D" advancement recreates the extracellular matrix. The platform studies cancer response to drugs within this microenvironment, enabling it to provide clinically relevant predictions to cancer patients. It is this capacity to study human tumor microenvironments that distinguishes it from other platforms in the field.